Live Science on MSN
Color blindness linked to lower bladder cancer survival, early study hints
People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...
I'm trained to treat conditions I used to see mainly in older patients - but now it's all teenagers and people in their early ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...
People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...
Needing to pee frequently throughout the night can be a hidden sign of some health conditions. These include diabetes, sleep ...
Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.
The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing Phase 2 ADVANCED-2 trial. ADVANCED-2 ...
A 40-year-old woman suffered recurrent urinary tract infections for six months before doctors discovered the infection had spread to her kidneys, putting her close to organ failure. Urologist Dr ...
Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.
ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...
The underactive bladder syndrome market is expected to grow steadily, driven by an aging global population and rising prevalence of neurogenic and chronic conditions affecting bladder function.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback